论文部分内容阅读
目的分析三九胃泰颗粒联合雷贝拉唑钠肠溶胶囊治疗慢性浅表性胃炎的效果及安全性。方法采用随机平行对照法将2015年2月至2016年3月103例慢性浅表性胃炎患者依据治疗方法不同分为对照组51例及观察组52例。对照组患者给予雷贝拉唑钠肠溶胶囊,观察组患者给予三九胃泰颗粒联合雷贝拉唑钠肠溶胶囊治疗。观察两组患者治疗后的临床疗效及安全性。结果观察组总有效率(98.08%)高于对照组(88.24%,P<0.05);观察组治疗期间不良反应发生率(7.69%)低于对照组(7.84%),但差异未见统计学意义(P>0.05)。结论三九胃泰颗粒联合雷贝拉唑钠肠溶胶囊,治疗慢性浅表性胃炎效果确切,安全性高,临床可广泛应用。
Objective To analyze the effect and safety of SanJiuWeiTai granule combined with rabeprazole sodium enteric-coated capsules in the treatment of chronic superficial gastritis. Methods 103 patients with chronic superficial gastritis between February 2015 and March 2016 were divided into control group (n = 51) and observation group (n = 52) according to the method of randomized parallelism. Control group patients given rabeprazole sodium enteric-coated capsules, observation group patients were given Sanjiuweitai granule combined with rabeprazole sodium enteric-coated capsules. The clinical efficacy and safety of the two groups after treatment were observed. Results The total effective rate (98.08%) in the observation group was higher than that in the control group (88.24%, P <0.05). The incidence of adverse reactions in the observation group was 7.69% less than that in the control group (7.84%), but the difference was not statistically significant Significance (P> 0.05). Conclusion Sanjiuweitai granule combined with rabeprazole sodium enteric-coated capsules, the treatment of chronic superficial gastritis exact effect, high safety, clinical can be widely used.